Oral

1022 - Unravelling the Clinical and Biological Features of Accelerated Chronic Lymphocytic Leukemia

1023 - Clinical and biological impact of MYC Overexpression in Chronic Lymphocytic Leukemia with and without TP53 Disruption

1024 - ROR1-Signaling Enhances Survival and Drug-Resistance of del(17p)/TP53-Mutated CLL by Mitigating Oxidative Stress Via Activation of NRF2

1121 - High-risk molecular features eclipse genomic complexity in predicting CLL patient outcomes; Insights from the UK CLL4, ARCTIC and ADMIRE trials.

1122 - Integrative epi(genome) analysis of CD49d bimodal expression reveals epigenetically driven phenotypic transitions in CLL

1311 - Targeted Degradation of NF-κB RelA/p65 by PBD-Based PROTACs as a Novel Therapeutic Strategy in Chronic Lymphocytic Leukaemia

1312 - Zelebrudomide (NX-2127) is a cereblon-modulating BTK degrader that reverses immune dysfunction and modifies both T-cell and CLL-cell transcriptional signatures in patients with CLL

1442 - NGS-based MRD assessment refines prognostication after venetoclax-based first-line combinations for chronic lymphocytic leukemia: A prospective analysis of the phase 3 GAIA/CLL13 trial

1606 - Epcoritamab Monotherapy in Patients with First-Line Richter’s Transformation: 2-Year Follow-Up Results From the Phase 1b/2 EPCORE CLL-1 Clinical Trial

1607 - MGA Loss drives cristae remodeling and redox adaptation via MICOS and PRDX2 in Richters transformation

1912 - A tandem CD19/ROR1 CAR-NK to overcome apoptotic resistance in chronic lymphocytic leukemia

2004 - Clinicopathological Features and Treatment Outcomes of Chronic Lymphocytic Leukemia in Pakistan: A Real-World Analysis